These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29384621)

  • 1. A Fresh Shine onCystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles.
    Jasim R; Schneider EK; Han M; Azad MAK; Hussein M; Nowell C; Baker MA; Wang J; Li J; Velkov T
    J Biomed Nanotechnol; 2017 Apr; 13(4):447-57. PubMed ID: 29384621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
    Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
    ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
    Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
    Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa.
    Lin YW; Yu HH; Zhao J; Han ML; Zhu Y; Akter J; Wickremasinghe H; Walpola H; Wirth V; Rao GG; Forrest A; Velkov T; Li J
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of silver nanoparticles and polymyxin B against biofilm produced by
    Salman M; Rizwana R; Khan H; Munir I; Hamayun M; Iqbal A; Rehman A; Amin K; Ahmed G; Khan M; Khan A; Amin FU
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2465-2472. PubMed ID: 31187657
    [No Abstract]   [Full Text] [Related]  

  • 6. Polymyxin B and ethylenediaminetetraacetic acid act synergistically against
    Hale SJM; Cameron AJ; Lux CA; Biswas K; Kim R; O'Carroll M; Harris PWR; Douglas RG; Wagner Mackenzie B
    Microbiol Spectr; 2024 Feb; 12(2):e0170923. PubMed ID: 38168683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics.
    Otto RG; van Gorp E; Kloezen W; Meletiadis J; van den Berg S; Mouton JW
    Int J Antimicrob Agents; 2019 Jan; 53(1):34-39. PubMed ID: 30240838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biogenic silver nanoparticle (Bio-AgNP) has an antibacterial effect against carbapenem-resistant Acinetobacter baumannii with synergism and additivity when combined with polymyxin B.
    Allend SO; Garcia MO; da Cunha KF; de Albernaz DTF; da Silva ME; Ishikame RY; Panagio LA; Nakazaro G; Reis GF; Pereira DB; Hartwig DD
    J Appl Microbiol; 2022 Feb; 132(2):1036-1047. PubMed ID: 34496109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens.
    Payne JE; Dubois AV; Ingram RJ; Weldon S; Taggart CC; Elborn JS; Tunney MM
    Int J Antimicrob Agents; 2017 Sep; 50(3):427-435. PubMed ID: 28666755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use.
    Jain J; Arora S; Rajwade JM; Omray P; Khandelwal S; Paknikar KM
    Mol Pharm; 2009; 6(5):1388-401. PubMed ID: 19473014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minocycline and Silver Dual-Loaded Polyphosphoester-Based Nanoparticles for Treatment of Resistant Pseudomonas aeruginosa.
    Chen Q; Shah KN; Zhang F; Salazar AJ; Shah PN; Li R; Sacchettini JC; Wooley KL; Cannon CL
    Mol Pharm; 2019 Apr; 16(4):1606-1619. PubMed ID: 30817887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.
    Hogardt M; Schmoldt S; Götzfried M; Adler K; Heesemann J
    J Antimicrob Chemother; 2004 Dec; 54(6):1057-61. PubMed ID: 15509615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
    Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
    J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii.
    Thomas VM; Brown RM; Ashcraft DS; Pankey GA
    Int J Antimicrob Agents; 2019 May; 53(5):663-668. PubMed ID: 30880230
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Chen H; Li H; Liu Z; Li J
    Microb Drug Resist; 2020 Sep; 26(9):1108-1119. PubMed ID: 32349617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.
    Schneider-Futschik EK; Paulin OKA; Hoyer D; Roberts KD; Ziogas J; Baker MA; Karas J; Li J; Velkov T
    ACS Infect Dis; 2018 May; 4(5):646-655. PubMed ID: 29566483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
    MacLeod DL; Barker LM; Sutherland JL; Moss SC; Gurgel JL; Kenney TF; Burns JL; Baker WR
    J Antimicrob Chemother; 2009 Oct; 64(4):829-36. PubMed ID: 19679597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against
    Hussein M; Allobawi R; Levou I; Blaskovich MAT; Rao GG; Li J; Velkov T
    Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxin B combinations with FDA-approved non-antibiotic phenothiazine drugs targeting multi-drug resistance of Gram-negative pathogens.
    Hussein M; Hu X; Paulin OKA; Crawford S; Tony Zhou Q; Baker M; Schneider-Futschik EK; Zhu Y; Li J; Velkov T
    Comput Struct Biotechnol J; 2020; 18():2247-2258. PubMed ID: 32952938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing High-Throughput Screening Identifies Unconventional Drugs with Antibacterial and Antibiofilm Activities against Pseudomonas aeruginosa under Experimental Conditions Relevant to Cystic Fibrosis.
    Di Bonaventura G; Lupetti V; Di Giulio A; Muzzi M; Piccirilli A; Cariani L; Pompilio A
    Microbiol Spectr; 2023 Aug; 11(4):e0035223. PubMed ID: 37306577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.